Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy :A Placebo-controlled Double-blind Randomized Phase III Study

ABSTRACT: Interventions: Goshajinkigan 7.5g/day, 12 course + mFOLFOX6 12 course Placebo 7.5g/day, 12 course + mFOLFOX6 12 course Primary outcome(s): TimeToGrade2+ (CTCAE v4.0) Neuropathy; TTN Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619732 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I study of the preventive effect of Kampo medicine on oxaliplatin-induced peripheral neurotoxicity

Project description:Interventions: During XELOX regimen, Kampo medicine is administered as follows: Level 1(TJ-18 7.5g, TJ-3023 0g), Level 2(TJ-18 7.5g, TJ-3023 1.5g), Level 3(TJ-18 7.5g, TJ-3023 3.0g) Primary outcome(s): Decision of DLT, MTD, RD of Kampo medicine (TJ-3023, TJ-18) Study Design: Single arm Non-randomized

| 2631410 | ecrin-mdr-crc

Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: A placebo-controlled double blind randomized Phase II study (The GONE Study)

Project description:Interventions: FOLFOX4(L-OHP85mg/m2, l-LV100mg/m2x2, 5FU400mg/m2(bolus)x2, 5FU600mg/m2x2(civ)) or mFOLFOX6(L-OHP85mg/m2, l-LV200mg/m2, 5FU400mg/m2(bolus), 5FU240mg/m2(civ)).Cycles of chemotherapy are given every 2 weeks until PD or unacceptable toxicity occurred. Goshajinkigan(GJG) is given orally at a dose of 2.5 g three times a day for 26 weeks starting on the day of L-OHP infusion. FOLFOX4(L-OHP85mg/m2, l-LV100mg/m2x2, 5FU400mg/m2(bolus)x2, 5FU600mg/m2x2(civ)) or mFOLFOX6(L-OHP85mg/m2, l-LV200mg/m2, 5FU400mg/m2(bolus), 5FU240mg/m2(civ)).Cycles of chemotherapy are given every 2 weeks until PD or unacceptable toxicity occurred. Placebo is given orally at a dose of 2.5 g three times a day for 26 weeks starting on the day of L-OHP infusion. Primary outcome(s): The incidence of peripheral neurotoxicity ≥grade 2 after eight cycles of chemotherapy. Study Design: Parallel Randomized

| 2617692 | ecrin-mdr-crc

Efficacy of Oral Administration of Cystine and Theanine in Colorectal Cancer Patients Undergoing Capecitabine based Adjuvant Chemotherapy after Surgery: Randomized, Double-blind, Placebo controlled, Phase-II Study

Project description:Interventions: One pack (Cystine 700 mg/day and Theanine 280 mg/day) to be taken after breakfast, daily oral administration One pack (placebo) to be taken after breakfast, daily oral administration Primary outcome(s): Incidence rate of Grade 1 or more diarrhea (CTCAE v4.0) Study Design: Parallel Randomized

| 2640026 | ecrin-mdr-crc

Preventive effect of shakuyaku-kanzo-to on neurotoxicity of FOLFOX plus bevacizumab for patients with metastatic colorectal cancer: a prospective phase II study

Project description:Interventions: Patients receive FOLFOX4 plus bevacizumab or modified FOLFOX6 plus bevacizumab and take shakuyaku-kanzo-to (7.5g/day) orally every day during FOLFOX plus bevacizumab treatment. Primary outcome(s): Neurotoxicity frequency of accumulation dose 500mg/m2 of oxaliplatin Study Design: Single arm Non-randomized

| 2617341 | ecrin-mdr-crc

Double-Blind , Placebo-Controlled Randomized Phase II Study of Hangeshashinto for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy (HANGESHA-C Study).

Project description:Interventions: Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals. Oral administration of Placebo 7.5g/day t.i.d. after meals. Primary outcome(s): Incidence of oral mucositis. grade>=2 Study Design: Parallel Randomized

| 2619737 | ecrin-mdr-crc

Open-label trial to evaluate the efficacy of pre-emptive therapy with minocycline and multidisciplinary intervention for skin toxicity of anti EGFR antibody in colorectal cancer patient

Project description:Interventions: Minocycline tablet 100mg once a day after dinner (for 4 weeks after the day starting to take anti EGFR antibody) Primary outcome(s): The incidence of >= Grade 2 skin toxicity (Dermatitis acneiform, Paronychia, Dry skin, Pruritus) during 4weeks after starting anti EGFR antibody (using CTCAE v4.0) Study Design: Single arm Non-randomized

| 2625494 | ecrin-mdr-crc

Modeling Alcohol-induced Neurotoxicity using Human Induced Pluripotent Stem Cell-derived Three-Dimensional Cerebral Organoids

Project description:We performed transcriptomic studies using microarray assays and conducted bioinformatics analyses to identify signaling pathways associated with ethanol-induced brain injury in cerebral organoids A human message RNA (mRNA) Expression Microarray assay (V4.0) and data analysis services were provided by Arraystar Inc. (Rockville, MD) to assess and compare the global abundance of 17,195 mRNAs across iPSC-derived 2-month cerebral organoids treated with and without ethanol.

2021-07-13 | GSE154934 | GEO

Pertubations of gene expresion by lapatinib or THZ1 in HER2 positive breast cancer cell lines.

Project description:Gene expression profiling were examined by Human HT-12 v4.0 Expression BeadChip arrays in SKBR3 and BT474 cells treated with HER2 inhibitor lapatinib or CDK7 inhibitor THZ1.

2021-05-21 | GSE129254 | GEO

Hsa-miR-500a-5p target discovery

Project description:Hsa-miR-500a-5p (miR500a) activity has been associated with breast cancer survival. We used gene expression arrays (Illumina HumanHT-12 V4.0) to discover relevant targets of miR500a.

2017-11-27 | GSE92564 | GEO

Expression profile of HCT116 cells treated with TNF-α/IFN-ɣ, both TNF-α/IFN-ɣ and silibinin, and without treatment.

Project description:Expression profiling of HCT116 colon cancer cells with different treatments. Illumina HumanHT-12 V4.0 expression beadchip was used to obtain expression profiles across more than 31,000 annotated genes.

2015-12-31 | GSE64131 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data